Moleculin Biotech Inc
NASDAQ:MBRX

Watchlist Manager
Moleculin Biotech Inc Logo
Moleculin Biotech Inc
NASDAQ:MBRX
Watchlist
Price: 4.83 USD -27.15% Market Closed
Market Cap: 10m USD

Operating Margin
Moleculin Biotech Inc

0%
Current
0%
Average
-3.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-24.2m
/
Revenue
0

Operating Margin Across Competitors

No Stocks Found

Moleculin Biotech Inc
Glance View

Market Cap
10m USD
Industry
Biotechnology

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2016-06-02. The firm has a pipeline of clinical programs for the treatment of highly resistant cancers and viruses. The company has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066 Portfolio (including lead drug candidates WP1066 and WP1220) represents a class of agents capable of hitting multiple targets, including the activated form of a key oncogenic transcription factor, STAT3. WP1066 is its flagship Immune/Transcription Modulator. An analog of WP1066, referred to as WP1220, is related to the use of the molecule in the topical treatment of psoriasis. The firm's WP1122 Portfolio and similar molecules focused on inhibitors of glycolysis and glycosylation.

MBRX Intrinsic Value
3.25 USD
Overvaluation 33%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-24.2m
/
Revenue
0
What is the Operating Margin of Moleculin Biotech Inc?

Based on Moleculin Biotech Inc's most recent financial statements, the company has Operating Margin of 0%.

Back to Top